In-Silico Analysis of 2-(Substituted-2h-Chromen-3-Yl)-5-Aryl-1himidazole Derivatives As An Anti-Angiogenesis Agents In Breast Cancer

Abstract

Based on earlier proven pharmacophore analogues of cancer a novel 2 (substituted-2H-chromen-3-yl)-5-aryl-1H-imidazoles (13–16) were rationally designed. Compounds 13–16 were screened in silico for the inhibition of KRAS/Wnt and their anti-angiogenesis properties. Compound 16f has been identified as a potent anti-angiogenesis molecule, which can be considered as a new lead structure. The molecular docking analysis displayed the higher binding affinity of 16f with KRAS, Wnt and VEGF.